Payment overview · 2025
General Payments
$76.02
4 reported records · 4 companies
Healthcare provider profile · identity verified
Jamie Ryan Ham, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GOLDSBORO, NC · NPI 1477912632
Verified facts
What the public records show
CMS Open Payments records show Jamie Ryan Ham, NP-C received $76.02 in general payments during 2025 across 4 reported records.
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $27.61 | 36.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.34 | 26.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.51 | 19.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.56 | 17.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $76.02 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 74 |
| Omeprazole | Omeprazole | 268 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 65 |
| Gabapentin | Gabapentin | 201 | 54 |
| Losartan Potassium | Losartan Potassium | 201 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 51 |
| Lisinopril | Lisinopril | 171 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 42 |
| Meloxicam | Meloxicam | 133 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 37 |
| Sertraline Hcl | Sertraline Hcl | 120 | 40 |
| Furosemide | Furosemide | 119 | 36 |
| Metformin Hcl | Metformin Hcl | 112 | 33 |
| Metformin Hcl Er | Metformin Hcl | 108 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 31 |
| Trazodone Hcl | Trazodone Hcl | 102 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 24 |
| Famotidine | Famotidine | 92 | 28 |
| Tramadol Hcl | Tramadol Hcl | 90 | 25 |
| Ezetimibe | Ezetimibe | 84 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 15 |
| Ozempic | Semaglutide | 77 | 17 |
| Alprazolam | Alprazolam | 76 | 21 |
| Eliquis | Apixaban | 76 | 17 |
| Lorazepam | Lorazepam | 75 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 20 |
| Allopurinol | Allopurinol | 72 | 22 |
| Potassium Chloride | Potassium Chloride | 71 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 20 |
| Bupropion Xl | Bupropion Hcl | 67 | 21 |
| Glimepiride | Glimepiride | 66 | 16 |
| Spironolactone | Spironolactone | 66 | 17 |
| Prednisone | Prednisone | 63 | 34 |
| Simvastatin | Simvastatin | 63 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 18 |
| Jardiance | Empagliflozin | 59 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 25 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 17 |
| Glipizide Er | Glipizide | 52 | 14 |
| Temazepam | Temazepam | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | 16 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Promethazine Hcl | Promethazine Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 17 |
| Donepezil Hcl | Donepezil Hcl | 46 | 14 |
| Celecoxib | Celecoxib | 45 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 11 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Carvedilol | Carvedilol | 41 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Ramipril | Ramipril | 39 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | 11 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 19 |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Topiramate | Topiramate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76.02 · 4 records | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | JARDIANCE, LifeVest, Ozempic, Rybelsus, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error